Metallothionein as a useful marker in Hodgkin lymphoma subclassification

References

• Alvaro T, Lejeune M, Garcia J F, Salvado M T, Lopez C, Bosch R, et al. Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells. Clin Cancer Res 2008; 14: 685–691
   PubMed Web of Science ®Google Scholar
• Bai M, Papoudou-Bai A, Kitsoulis P, Horianopoulos N, Kamina S, Agnantis N J, et al. Cell cycle and apoptosis deregulation in classical Hodgkin lymphomas. In Vivo 2005; 19: 439–453
   PubMed Web of Science ®Google Scholar
• Higgins R A, Blankenship J E, Kinney M C. Application of immunohistochemistry in the diagnosis of non-Hodgkin and Hodgkin lymphoma. Arch Pathol Lab Med 2008; 132: 441–461
   PubMed Web of Science ®Google Scholar
• Nogova L, Reineke T, Brillant C, Sieniawski M, Rudiger T, Josting A, et al. Lymphocytepredominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008; 26: 434–439
   PubMed Web of Science ®Google Scholar
• Borlado L R, Mendez J. CDC6: from DNA replication to cell cycle checkpoints and oncogenesis. Carcinogenesis 2008; 29: 237–243
   PubMed Web of Science ®Google Scholar
• Cai L, Cherian M G. Zinc-metallothionein protects from DNA damage induced by radiation better than glutathione and copper- or cadmium-metallothioneins. Toxicol Lett 2003; 136: 193–198
   PubMed Web of Science ®Google Scholar
• Gambichler T, Bischoff S, Bechara F G, Altmeyer P, Kreuter A. Expression of proliferation markers and cell cycle regulators in T cell lymphoproliferative skin disorders. J Dermatol Sci 2008; 49: 125–132
   PubMed Web of Science ®Google Scholar
• Nielsen A E, Bohr A, Penkowa M. The balance between life and death of cells: roles of metallothioneins. Biomark Insights 2007; 2: 99–111
   Google Scholar
• Qu W, Fuquay R, Sakurai T, Waalkes M P. Acquisition of apoptotic resistance in cadmium-induced malignant transformation: specific perturbation of JNK signal transduction pathway and associated metallothionein overexpression. Mol Carcinog 2006; 45: 561–571
   PubMed Web of Science ®Google Scholar
• Sjo L D, Poulsen C B, Hansen M, Moller M B, Ralfkiaer E. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol 2007; 79: 501–507
   PubMed Web of Science ®Google Scholar
• Zatta P, Zambenedetti P, Musicco M, Adorni F. Metallothionein-I-II and GFAP positivity in the brains from frontotemporal dementia patients. J Alzheimers Dis 2005; 8: 109–116, 209–215
   PubMed Web of Science ®Google Scholar
• Cherian M G, Kang Y J. Metallothionein and liver cell regeneration. Exp Biol Med (Maywood) 2006; 231: 138–144
   PubMed Web of Science ®Google Scholar
• Chung R S, Penkowa M, Dittmann J, King C E, Bartlett C, Asmussen J W, et al. Redefining the role of metallothionein within the injured brain: extracellular metallothioneins play an important role in the astrocyte-neuron response to injury. J Biol Chem 2008; 283: 15349–15358
   PubMed Web of Science ®Google Scholar
• Coyle P, Philcox J C, Carey L C, Rofe A M. Metallothionein: the multipurpose protein. Cell Mol Life Sci 2002; 59: 627–647
   PubMed Web of Science ®Google Scholar
• Hidalgo J, Penkowa M, Espejo C, Martinez-Caceres E M, Carrasco J, Quintana A, et al. Expression of metallothionein-I, -II, and -III in Alzheimer disease and animal models of neuroinflammation. Exp Biol Med (Maywood) 2006; 231: 1450–1458
   PubMed Web of Science ®Google Scholar
• Krezel A, Maret W. Different redox states of metallothionein/thionein in biological tissue. Biochem J 2007; 402: 551–558
   PubMed Web of Science ®Google Scholar
• Penkowa M. Metallothioneins are multipurpose neuroprotectants during brain pathology. FEBS J 2006; 273: 1857–1870
   PubMed Web of Science ®Google Scholar
• Carpene E, Andreani G, Isani G. Metallothionein functions and structural characteristics. J Trace Elem Med Biol 2007; 21(Suppl 1)35–39
   PubMed Web of Science ®Google Scholar
• Simpkins C O. Metallothionein in human disease. Cell Mol Biol (Noisy-le-grand) 2000; 46: 465–488
   PubMed Web of Science ®Google Scholar
• Stankovic R K, Chung R S, Penkowa M. Metallothioneins I and II: neuroprotective significance during CNS pathology. Int J Biochem Cell Biol 2007; 39: 484–489
   PubMed Web of Science ®Google Scholar
• Theocharis S E, Margeli A P, Koutselinis A. Metallothionein: a multifunctional protein from toxicity to cancer. Int J Biol Markers 2003; 18: 162–169
   PubMed Web of Science ®Google Scholar
• Thirumoorthy N, Manisenthil Kumar K T, Shyam Sundar A, Panayappan L, Chatterjee M. Metallothionein: an overview. World J Gastroenterol 2007; 13: 993–996
   PubMed Web of Science ®Google Scholar
• Faurschou M, Penkowa M, Andersen C B, Starklint H, Jacobsen S. The renal metallothionein expression profile is altered in human lupus nephritis. Arthritis Res Ther 2008; 10: R76
   PubMed Web of Science ®Google Scholar
• Huh S, Lee K, Yun H S, Paik D J, Kim J M, Youn J. Functions of metallothionein generating interleukin-10-producing regulatory CD4+ T cells potentiate suppression of collagen induced arthritis. J Microbiol Biotechnol 2007; 17: 348–358
   PubMed Web of Science ®Google Scholar
• Penkowa M, Espejo C, Ortega-Aznar A, Hidalgo J, Montalban X, Martinez Caceres E M. Metallothionein expression in the central nervous system of multiple sclerosis patients. Cell Mol Life Sci 2003; 60: 1258–1266
   PubMed Web of Science ®Google Scholar
• Scheede-Bergdahl C, Penkowa M, Hidalgo J, Olsen D B, Schjerling P, Prats C, et al. Metallothionein-mediated antioxidant defense system and its response to exercise training are impaired in human type 2 diabetes. Diabetes 2005; 54: 3089–3094
   PubMed Web of Science ®Google Scholar
• Gonçalves I, Quintela T, Baltazar G, Almeida M R, Saraiva M J, Santos C R. Transthyretin interacts with metallothionein 2. Biochemistry 2008; 47: 2244–2251
   PubMed Web of Science ®Google Scholar
• Cherian M G, Jayasurya A, Bay B H. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res 2003; 533: 201–209
   PubMed Web of Science ®Google Scholar
• Dziegiel P. Expression of metallothioneins in tumor cells. Pol J Pathol 2004; 55: 3–12
   PubMedGoogle Scholar
• Penkowa M, Carrasco J, Giralt M, Molinero A, Hernandez J, Campbell I L, et al. Altered central nervous system cytokine-growth factor expression profiles and angiogenesis in metallothionein-I+II deficient mice. J Cereb Blood Flow Metab 2000; 20: 1174–1189
   PubMed Web of Science ®Google Scholar
• Suntres Z E, Lui E M. Antioxidant effect of zinc and zinc-metallothionein in the acute cytotoxicity of hydrogen peroxide in Ehrlich ascites tumour cells. Chem Biol Interact 2006; 162: 11–23
   PubMed Web of Science ®Google Scholar
• Tsangaris G T, Vamvoukakis J, Politis I, Kattamis A C, Tzortzatou-Stathopoulou F. Metallothionein expression prevents apoptosis. II. Evaluation of the role of metallothionein expression on the chemotherapy-induced apoptosis during the treatment of acute leukemia. Anticancer Res 2000; 20: 4407–4411
   PubMed Web of Science ®Google Scholar
• Sauerbrey A, Zintl F, Hermann J, Volm M. Multiple resistance mechanisms in acute nonlymphoblastic leukemia (ANLL). Anticancer Res 1998; 18: 1231–1236
   PubMed Web of Science ®Google Scholar
• Sauerbrey A, Zintl F, Volm M. Expression of metallothionein in initial and relapsed childhood acute lymphoblastic leukemia. Ann Hematol 1994; 69: 111–115
   PubMed Web of Science ®Google Scholar
• Theocharis S E, Margeli A P, Klijanienko J T, Kouraklis G P. Metallothionein expression in human neoplasia. Histopathology 2004; 45: 103–118
   PubMed Web of Science ®Google Scholar
• Abdel-Mageed A, Agrawal K C. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther 1997; 4: 199–207
   PubMed Web of Science ®Google Scholar
• Lazo J S, Kuo S M, Woo E S, Pitt B R. The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. Chem Biol Interact 1998; 111–112: 255–262
   PubMed Web of Science ®Google Scholar
• Yamasaki M, Nomura T, Sato F, Mimata H. Metallothionein is up-regulated under hypoxia and promotes the survival of human prostate cancer cells. Oncol Rep 2007; 18: 1145–1153
   PubMed Web of Science ®Google Scholar
• Yang M, Kroft S H, Chitambar C R. Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate. Mol Cancer Ther 2007; 6: 633–643
   PubMed Web of Science ®Google Scholar
• Poulsen C B, Borup R, Borregaard N, Nielsen F C, Moller M B, Ralfkiaer E. Prognostic significance of metallothionein in B-cell lymphomas. Blood 2006; 108: 3514–3519
   PubMed Web of Science ®Google Scholar
• Rizkalla K S, Cherian M G. Metallothionein: a potential marker for differentiating benign and neoplastic gastrointestinal lymphoid inltrates. Pathology 1997; 29: 141–146
   PubMed Web of Science ®Google Scholar
• Meskel H H, Cherian M G, Martinez V J, Veinot L A, Frei J V. Metallothionein as epithelial proliferative compartment marker for DNA flow cytometry. Mod Pathol 1993; 6: 755–760
   PubMed Web of Science ®Google Scholar
• Jayasurya A, Bay B H, Yap W M, Tan N G. Infiltrating lymphocytes in undifferentiated nasopharyngeal cancer lack metallothionein expression. Cancer Lett 2000; 155: 99–104
   PubMed Web of Science ®Google Scholar
• Carbone P P, Kaplan H S, Musshoff K, Smithers D W, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Hollowood K, Macartney J C. Reduced apoptotic cell death in follicular lymphoma. J Pathol 1991; 163: 337–342
   PubMed Web of Science ®Google Scholar
• Nomura Y, Sugita Y, Yoshida S, Karube K, Shimizu K, Aoki R, et al. Estimation of apoptosis and cell proliferation in histiocytic necrotizing lymphadenitis using immunohistochemical double staining. Pathol Int 2008; 58: 98–103
   PubMed Web of Science ®Google Scholar
• Jaffe, E S, Harris, N L, Stein, H, Vardiman, J W. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues1st edn. Lyon, France, IARC Press. 2001
   Google Scholar
• Tews D S, Fleissner C, Tiziani B, Gaumann A K. Intrinsic expression of drug resistance associated factors in meningiomas. Appl Immunohistochem Mol Morphol 2001; 9: 242–249
   PubMedGoogle Scholar
• Dutsch-Wicherek M, Popiela T J, Klimek M, Rudnicka-Sosin L, Wicherek L, Oudinet J P, et al. Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. Neuro Endocrinol Lett 2005; 26: 567–574
   PubMed Web of Science ®Google Scholar
• Ishii K, Usui S, Yamamoto H, Sugimura Y, Tatematsu M, Hirano K. Decreases of metallothionein and aminopeptidase N in renal cancer tissues. J Biochem 2001; 129: 253–258
   PubMed Web of Science ®Google Scholar
• Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, Gorzynska E, et al. Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in laryngeal cancer. Anticancer Res 2007; 27: 335–342
   PubMed Web of Science ®Google Scholar
• Suzuki J S, Nishimura N, Zhang B, Nakatsuru Y, Kobayashi S, Satoh M, et al. Metallothionein deficiency enhances skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate in metallothioneinnull mice. Carcinogenesis 2003; 24: 1123–1132
   PubMed Web of Science ®Google Scholar
• Datta J, Majumder S, Kutay H, Motiwala T, Frankel W, Costa R, et al. Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein α by phosphatidylinositol 3-kinase signaling cascade. Cancer Res 2007; 67: 2736–2746
   PubMed Web of Science ®Google Scholar
• Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L, et al. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 2008; 88: 474–481
   PubMed Web of Science ®Google Scholar
• Huang Y, de la Chapelle A, Pellegata N S. Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 2003; 104: 735–744
   Google Scholar
• Mitani T, Shirasaka D, Aoyama N, Miki I, Morita Y, Ikehara N, et al. Role of metallothionein in Helicobacter pylori-positive gastric mucosa with or without early gastric cancer and the effect on its expression after eradication therapy. J Gastroenterol Hepatol 2008; 23: e334–e339
   PubMed Web of Science ®Google Scholar